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In the first half of 2004, acute hepatitis E virus infections
diagnosed in Victoria, Australia, increased 7-fold. Of the
interviewed patients with highly reactive serologic results,
90% reported recent clinically compatible illness and over-
seas travel. The increase is compared with a background of
exposure in countries in which hepatitis E is endemic.
H
epatitis E virus (HEV) is a major cause of enterically
transmitted hepatitis worldwide. It is an important
pathogen in Asia, the Middle East, and parts of Africa and
Central America (1,2). Epidemic HEV is manifested in
waterborne outbreaks, often involving thousands of peo-
ple, which predominantly occur in areas where environ-
mental sanitation facilities are inadequate. However,
endemic (sporadic) HEV accounts for the majority of
infections (2). In India, HEV is responsible for 50% to
70% of all cases of sporadic viral hepatitis (1).
HEV seroprevalence in disease-nonendemic areas such
as Australia is low, ≈1% to 2% (3–5), in contrast to disease-
endemic areas where seroprevalence increases as residents
increase in age from 10% to 40% in adults (1,3,5,6). Some
of this seropositivity is explained by subclinical infection
and by persistence of immunoglobulin (Ig) G against HEV,
which has been detected <14 years after infection (7).
The incubation period for HEV is 2 to 9 weeks, and the
spectrum of disease ranges from subclinical infection to
fulminant hepatitis. Clinical features can include fever,
chills, jaundice, dark urine, anorexia, nausea, vomiting,
abdominal pain, headache, myalgia, and arthralgia (1–3).
In general, HEV infection is more likely to be subclin-
ical in children (1). Although usually a self-limiting dis-
ease with death rate <1%, a high incidence of fulminant
hepatitis is seen in pregnant women, in whom the death
rate can exceed 20% in the third trimester (2,3). HEV does
not lead to persistent infection or chronic hepatitis (1,2).
No vaccine is currently available.
In disease-nonendemic countries such as Australia,
almost all patients with HEV infection report recent
travel to areas where the disease was endemic (1,2,5). New
evidence, however, suggests that HEV is more prevalent in
industrialized countries than previously thought (8) and
that zoonotic transmission may be implicated (1,2,5).
As in many jurisdictions, hepatitis E must be reported
as an infectious disease throughout Australia. In Victoria,
the Department of Human Services must be notified by
both the treating doctor and the testing laboratory. In the
first 6 months of 2004, an increase in positive hepatitis E
serologic results was observed at the Victorian Infectious
Diseases Reference Laboratory, a state reference and pub-
lic health laboratory. Investigations to determine whether
these serologic results represented true acute hepatitis E
infections were conducted. 
The Study
To fulfill the Victorian hepatitis E case definition for
surveillance purposes, one must demonstrate seroconver-
sion, a 4-fold rise in paired serum specimens or detect high-
ly reactive IgG in a single specimen in the presence of a
clinically compatible illness (9). Two commercial tests
have been used for HEV serologic testing at the Victorian
Infectious Diseases Reference Laboratory, the Abbott HEV
enzyme immunoassay (EIA) (Abbott GmbH Diagnostika,
Wiesbaden-Denkenheim, Germany) before March 2004
and the Genelabs HEV enzyme-linked immunosorbent
assay (ELISA) (Genelabs Diagnostics Pte Ltd., Singapore)
after March 2004. These tests detect anti-HEV IgG in the
patient’s serum by using recombinant antigens from the
structural region of the HEV genome (3,4). Internal
Victorian Infectious Diseases Reference Laboratory valida-
tion confirmed concordance of results using these tests, and
both produced highly reactive results in this case series.
Specimens are referred to the Victorian Infectious Diseases
Reference Laboratory from private pathology laboratories,
hospitals, and general practitioners throughout Victoria and
also from other states and countries.
The EIA result is expressed as the ratio of the
absorbance of the patient sample to the assay cut-off
absorbance (s/co). A sample with a ratio of >1.0 is consid-
ered positive. A high s/co ratio indicates highly reactive
patient serum, which suggests recent infection (2,6,10).
Anti-HEV Ig G titers peak from 2 to 4 weeks after disease
onset (11,12) and diminish relatively rapidly thereafter
(2,8,10–12). For the purposes of this study, we have
defined highly reactive results as those with an s/co ratio
of >5.0, which has been associated with recent infection
(12) and the presence of anti-HEV Ig M (13). Testing for
antihepatitis E Ig M was not performed.
For the first 2 quarters of 2004, 7 and 10 highly reac-
tive (s/co >5.0) hepatitis E EIAresults were found, respec-
tively. Both figures were the highest to date, and well
above 1.2, the quarterly mean number of highly reactive
results for the previous 5 years (p < 0.0001,  χ2 test)
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*Royal Melbourne Hospital, Parkville, Victoria, Australia;
†Department of Human Services, Melbourne, Victoria, Australia;
and ‡Victorian Infectious Diseases Reference Laboratory, North
Melbourne, Victoria, Australia(Figure 1). Ten highly reactive specimens were from
Victorian patients, compared to an expected number of 1.1
for the 6-month period (p < 0.0001). Total positive results
(all s/co > 1.0) for the first 2 quarters of 2004 were also
significantly increased at 7 (p = 0.0103) and 12 (p <
0.0001) compared to 2.75, the quarterly mean for the pre-
vious 5 years. 
All highly reactive HEV EIA results detected at the
Victorian Infectious Diseases Reference Laboratory are
reported to the Department of Human Services. Victorian
case-patients (those whose specimens are referred for test-
ing by a Victorian doctor) are investigated by means of a
standard questionnaire administered through telephone
contact with both the patient and his or her doctor to deter-
mine clinical details, travel history, and other information.
For patients outside Victoria, the appropriate authorities
are notified wherever possible. 
The 17 highly reactive samples tested at the Victorian
Infectious Diseases Reference Laboratory during the first
2 quarters of 2004 accounted for all hepatitis E notifica-
tions in the state during this period. However, only 2 of
these patients were also notified by the treating doctor, as
required by legislation. 
Nine of the 10 Victorian patients reported having been
in a disease-endemic area within the incubation period and
also having experienced an illness clinically compatible
with HEV infection. (For further clinical and epidemiolog-
ic data, refer to Online Table, available from
http://www.cdc.gov/ncidod/eid/04-706.htm#table.) The
remaining patient reported no compatible illness and,
therefore did not meet the Victorian case definition for sur-
veillance. He last travelled in a disease-endemic area
(Pakistan) in 2001. 
Except for 1 patient whose serum tested positive for
antibodies to hepatitis B core antigen, no positive serolog-
ic results for other hepatitis viruses (including hepatitis A)
were reported in the patients from Victoria. Four of the 7
specimens from non-Victorian residents had been collect-
ed from patients from India and sent by a private laborato-
ry to the Victorian Infectious Diseases Reference
Laboratory, and 3 specimens were from patients from
other states.
Conclusions
We found a 7-fold increase in the number of serum sam-
ples that were highly reactive for anti-HEV Ig G tested at
the Victorian Infectious Diseases Reference Laboratory in
the first half of 2004, from a mean for the last 5 years of 2.4,
to 17 (p < 0.0001). Ten of these specimens were from
patients in Victoria, a notable increase from the mean num-
ber for the previous 5 years of 1.1 for the 6-month period
(p < 0.0001). As is characteristic in a disease-nonendemic
region, 9 of the 10 highly reactive Victoria serum samples
tested in this period were from patients who had recently
traveled in disease-endemic countries, namely, India, Sri
Lanka, Thailand, and Vietnam.
Why HEV infections in Victoria have recently
increased cannot be established with certainty. Possible
explanations include an increase in the number of tests per-
formed, an increase in HEV activity in the countries visit-
ed by the travelers, an increase in the number of travelers
to or from disease-endemic areas, and changes in behavior
among the travelers. The last 2 possibilities are beyond the
scope of this article but merit further consideration. The
first 2 are explored further.
The mean number of hepatitis E serologic tests per-
formed at the Victorian Infectious Diseases Reference
Laboratory per quarter over the previous 5 years was 51.6
(Figure 2). In the first 2 quarters of 2004, respectively, 57
and 59 tests were performed, which is not significantly dif-
ferent from what was seen in previous quarters (p = 0.452
and 0.303).
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Figure 1. Highly reactive hepatitis E virus (HEV) enzyme-linked
immunosorbent assay results at the Victorian Infectious Diseases
Reference Laboratory per quarter, January 1, 1999, to June 30,
2004.
Figure 2. Total number of hepatitis E virus (HEV) enzyme-linked
immunosorbent assays performed at the Victorian Infectious
Diseases Reference Laboratory per quarter, January 1, 1999, to
June 30, 2004. Overseas hepatitis E activity does appear to have
increased during this period. ProMED-mail, the global
electronic reporting program for emerging diseases hosted
by the International Society for Infectious Diseases,
reported  >800 cases of hepatitis E infection in eastern
Calcutta, India, on April 23, 2004 (14). Contaminated
water pipelines were implicated. Other areas with hepatitis
E outbreaks reported by ProMED-mail in the first half of
2004 included Bangui, Central African Republic
(6/19/2004), Punjab, Pakistan (6/6/2004), Sadr, Iraq
(6/2/2004), and Gujarat, India (5/5/2004).
The first confirmed outbreak of hepatitis E with
≈29,000 cases of hepatitis occurred in Delhi in 1955–1956
when raw sewage contaminated drinking water during
heavy flooding (2,11,14). Other epidemics include
Kashmir in 1978, with an estimated 52,000 cases of hepa-
titis and 1,560 deaths (8), and the largest epidemic on
record in northwest China in 1986–1988 with >100,000
cases (15).
Increased diagnoses of hepatitis E in Victorian travelers
may have provided “early warning” of an evolving out-
break in an HEV-endemic area, particularly if a similar
increase is reported in other non–HEV-endemic areas.
Residents of resource-rich, non–disease-endemic countries
such as Australia likely have greater access to hepatitis E
testing than those living in resource-poor, HEV-endemic
areas where the greatest incidence of this disease occurs. 
Persons traveling to developing countries must be
advised of preventive measures they should take against
hepatitis E and other enterically transmitted diseases.
Hepatitis E infection should be considered in any febrile
person who has recently traveled in a disease-endemic
area, particularly if jaundice or abnormal liver function
tests are found, and especially in pregnant women due to
the risk of fulminant hepatitis. Cases should be reported to
public health authorities according to local legislation. 
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